Abstract
The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Keywords: proteins, hetero-oligomerization
Current Cancer Drug Targets
Title: Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents
Volume: 4 Issue: 2
Author(s): V. Gupta, D. P. Harkin, H. Kawakubo and S. Maheswaran
Affiliation:
Keywords: proteins, hetero-oligomerization
Abstract: The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Export Options
About this article
Cite this article as:
Gupta V., Harkin P. D., Kawakubo H. and Maheswaran S., Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481542
DOI https://dx.doi.org/10.2174/1568009043481542 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Directing Minimal Invasive Image Guided Therapy of Hepatic Colorectal Cancer Metastases – Imaging Strategies for Patient Evaluation, Therapy Planning, Therapy Monitoring, and Follow-Up
Current Medical Imaging Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Identification of Tumor Targeting Agents by Phage Display
Medicinal Chemistry Reviews - Online (Discontinued) An Optimised Radiolabel Procedure to Prepare 99mTc-Colloidal Rhenium Sulphide to Improve Radiochemical Purity
Current Radiopharmaceuticals Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry Cross-Talk between Oxidative Stress and Pro-Inflammatory Cytokines in Acute Pancreatitis: A Key Role for Protein Phosphatases
Current Pharmaceutical Design Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
Combinatorial Chemistry & High Throughput Screening Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews Respiration and Energy Homeostasis
Current Respiratory Medicine Reviews FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery
Current Pharmaceutical Design ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
Anti-Cancer Agents in Medicinal Chemistry DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Ion Transporters in Brain Tumors
Current Medicinal Chemistry A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Antitumor Activity of Novel N-Benzoyl-N'-substituted Pyrimidinyl (Thio)semicarbazide Derivatives
Letters in Drug Design & Discovery IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Advances and Perspectives in Cancer Nanotherapy: The Added- Value of Nanocarriers
Current Nanomedicine